Pearls in a shell


Immunology & Inflammation
HBM contact
Company status

Transforming the lives of patients living with immune-mediated diseases using a precision approach.

Alumis is developing ESK-001, a highly selective and potentially best-in-class allosteric tyrosine kinase 2 (TYK2) inhibitor, in moderate to severe plaque psoriasis and plans to initiate Phase 3 clinical trials in the second half of 2024. ESK-001 is also being tested in two ongoing Phase 2 clinical trials in systemic lupus erythematosus (SLE), and non-infectious uveitis. Alumis is also developing A-005, a TYK2 inhibitor for the treatment of neuroinflammatory and neurodegenerative diseases, as well as earlier-stage internal pipeline programs.